Work

Supplementary Table S5. Individual Patient Data Meta-Analysis - Randomized Trials from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Table 5 describes the 5 randomized trials of GO plus chemotherapy reviewed as part of the safety assessment of GO in combination with chemotherapy.

DOI: 10.1158/1078-0432.22470132

Authors: Emily Y. Jen, Chia-Wen Ko, Jee Eun Lee, Pedro L. Del Valle, Antonina Aydanian, Charles Jewell, Kelly J. Norsworthy, Donna Przepiorka, Lei Nie, Jiang Liu, Christopher M. Sheth, Marjorie Shapiro, Ann T. Farrell, Richard Pazdur

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361817757

Cites:

Cited by:

Related to: 10